Table 1 Clinical-pathological characteristics of locally advanced gastric cancer patients with neoadjuvant chemotherapy according to the lymph node ratio
Variables | Total (n = 148) | Low-LNR (n = 103) | High-LNR (n = 45) | P |
|---|---|---|---|---|
Gender | 0.146 | |||
Male | 122 | 88 (85.4%) | 34 (75.6%) | |
Female | 26 | 15 (14.6%) | 11 (24.4%) | |
Age | 0.757 | |||
< 65 y | 111 | 78 (75.7%) | 33 (73.3%) | |
≥ 65 y | 37 | 25 (24.3%) | 12 (26.7%) | |
Tumor location | 0.620 | |||
Upper stomach | 94 | 68 (66.0%) | 26 (57.8%) | |
Middle stomach | 19 | 12 (11.7%) | 7 (15.6%) | |
Lower stomach | 35 | 23 (22.3%) | 12 (26.7%) | |
NACT regimen | 0.098 | |||
FOLFOX | 81 | 51 (49.5%) | 30 (66.7%) | |
SOX | 55 | 45 (43.7%) | 10 (22.2%) | |
XELOX | 7 | 4 (3.9%) | 3 (6.7%) | |
FLOT | 5 | 3 (2.9%) | 2 (4.4%) | |
NACT cycle | 0.174 | |||
< 3 | 73 | 47 (45.6%) | 26 (57.8%) | |
≥ 3 | 75 | 56 (54.4%) | 19 (42.2%) | |
Operation method | 0.121 | |||
Laparoscopic | 80 | 60 (58.3%) | 20 (44.4%) | |
Open | 68 | 43 (41.7%) | 25 (55.6%) | |
Resection type | 0.226 | |||
Proximal | 30 | 23 (22.3%) | 7 (15.6%) | |
Distal | 21 | 17 (16.5%) | 4 (8.9%) | |
Total | 97 | 63 (61.2%) | 34 (75.6%) | |
Number of lymph node harvested | 25.3 ± 9.5 | 21.3 ± 7.4 | 0.486 | |
Histologic grade | .082 | |||
Well | 8 | 7 (6.8%) | 1 (2.2%) | |
Moderately | 37 | 30 (29.1%) | 7 (15.6%) | |
Poorly | 103 | 66 (64.1%) | 37 (82.2%) | |
Margin status | 0.287 | |||
R0 | 134 | 95 (92.2%) | 39 (86.7%) | |
R1 | 14 | 8 (7.8%) | 6 (13.3%) | |
TRG | .012 | |||
0 | 5 | 5 (4.9%) | 0 (0%) | |
1 | 15 | 14 (13.6%) | 1 (2.2%) | |
2 | 43 | 33 (32.0%) | 10 (22.2%) | |
3 | 85 | 51 (49.5%) | 34 (75.6%) | |
ypT stage | .002 | |||
0 | 5 | 5 (4.9%) | 0 (0%) | |
1 | 15 | 15 (14.6%) | 0 (0%) | |
2 | 15 | 13 (12.6%) | 2 (4.4%) | |
3 | 67 | 46 (44.7%) | 21 (46.7%) | |
4 | 46 | 24 (23.3%) | 22 (48.9%) | |
Postoperative complications | 0.787 | |||
Yes | 36 | 25 (24.3%) | 10 (22.2%) | |
No | 113 | 78 (75.7%) | 35 (77.8%) | |
Hospital stay | 0.201 | |||
≤ 12 days | 118 | 85 (82.5%) | 33 (73.3%) | |
> 12 days | 30 | 18 (17.5%) | 12 (26.7%) | |
Postoperative chemotherapy | 0.696 | |||
Yes | 118 | 83 (80.6%) | 35 (77.8%) | |
No | 30 | 20 (19.4%) | 10 (22.2%) | |